Carlson Capital Management Buys 58 Shares of Eli Lilly and Company (NYSE:LLY)

Carlson Capital Management increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.4% in the 3rd quarter, Holdings Channel reports. The firm owned 2,449 shares of the company’s stock after buying an additional 58 shares during the period. Carlson Capital Management’s holdings in Eli Lilly and Company were worth $2,170,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. Jacobs Levy Equity Management Inc. lifted its position in Eli Lilly and Company by 357.0% during the first quarter. Jacobs Levy Equity Management Inc. now owns 11,074 shares of the company’s stock valued at $8,615,000 after purchasing an additional 8,651 shares in the last quarter. Dynasty Wealth Management LLC purchased a new position in Eli Lilly and Company in the first quarter worth about $698,000. Ancora Advisors LLC raised its position in Eli Lilly and Company by 0.8% during the first quarter. Ancora Advisors LLC now owns 6,763 shares of the company’s stock valued at $5,261,000 after purchasing an additional 52 shares during the period. Creekmur Asset Management LLC boosted its holdings in shares of Eli Lilly and Company by 69.5% in the 1st quarter. Creekmur Asset Management LLC now owns 222 shares of the company’s stock worth $173,000 after purchasing an additional 91 shares during the period. Finally, Tidal Investments LLC raised its holdings in Eli Lilly and Company by 24.4% during the 1st quarter. Tidal Investments LLC now owns 38,519 shares of the company’s stock valued at $29,966,000 after buying an additional 7,559 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent research reports. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. Guggenheim increased their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective on the stock. Finally, Berenberg Bank raised their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,007.94.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded up $35.22 during trading on Tuesday, hitting $790.22. The company had a trading volume of 2,195,485 shares, compared to its average volume of 3,198,995. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The stock has a fifty day simple moving average of $861.63 and a two-hundred day simple moving average of $870.20. Eli Lilly and Company has a fifty-two week low of $561.65 and a fifty-two week high of $972.53. The firm has a market capitalization of $750.17 billion, a price-to-earnings ratio of 81.62, a price-to-earnings-growth ratio of 2.83 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. During the same period last year, the firm posted $0.10 EPS. The business’s quarterly revenue was up 20.4% on a year-over-year basis. On average, research analysts expect that Eli Lilly and Company will post 13.2 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a $1.30 dividend. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.66%. Eli Lilly and Company’s payout ratio is 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.